中信证券股份有限公司 关于上海三友医疗器械股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1 中信证券股份有限公司（以下简称"中信证券"）受上海三友医疗器械股份 有限公司（以下简称"三友医疗"）股东 QM5 LIMITED、上海隹正企业管理合 伙企业（有限合伙）（以下合称"出让方"）委托，组织实施本次三友医疗首发 前股东向特定机构投资者询价转让（以下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司股东以向特定机构投资者询价转让和配售方式减 持股份实施细则》（以下简称"《实施细则》"）等相关规定，中信证券对参与 本次询价转让股东的相关资格进行核查，并出具本核查意见。 一、本次询价转让的委托 中信证券陆续收到出让方关于本次询价转让的委托，委托中信证券组织实施 本次询价转让。 二、关于参与本次询价转让股东相关资格的核查情况 1、QM5 LIMITED （一）核查过程 根据相关法规要求，中信证券 ...

证券代码：688085 证券简称：三友医疗 公告编号：2023-037 上海三友医疗器械股份有限公司 股东询价转让计划书 QM5 Limited、上海隹正企业管理合伙企业（有限合伙）（以下合称"出让 方"）保证向上海三友医疗器械股份有限公司（以下简称"三友医疗"）提供的 信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确 性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中信证券股份有限公司（以下简称"中信证券"）组织实施本次 询价转让。截至 2023 年 12 月 7 日出让方所持首发前股份的数量、占总股本比例 情况如下： | 序号 | 股东名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | | 1 | QM5 Limited | 43,440,005 | 17.48% | | 2 | 上海隹正企业管理合伙企业（有限 | 18,747,000 | 7.55% | | | 合伙） | | | 1 拟参 ...

证券代码：688085 证券简称：三友医疗 公告编号：2023-036 上海三友医疗器械股份有限公司 关于参与认购法国 Implanet 公司公开发行股份的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1 投资标的名称：Implanet SA（以下简称"Implanet"或"Implanet 公 司"），法国巴黎泛欧交易所骨科上市公司，股票代码：ALIMP 交易内容简述：公司拟使用自有资金 500 万欧元，通过全资子公司三友 （香港）國際醫療控股有限公司认购 Implanet 公司的公开发行股份。 本次投资前公司持有 Implanet 公司 41.03%的股权，本次投资完成后， 公司对 Implanet 公司的持股比例约增加至 78.48%-85.42%，Implanet 公 司将成为公司的控股孙公司，Implanet 公司将纳入公司合并报表范围之 内。 对上市公司的影响：（1）公司本次对外投资完成后，公司将在国际高端 骨科市场拥有一个具有独立研发能力和完备质量体系及公司建制的实 体公司，可以利用 ...

Group 1: Product Offerings and Innovations - BAGUERA-C artificial cervical disc replacement is included in the national spinal material procurement range, with a bid price of 11,190 yuan [1] - The company has developed a series of innovative orthopedic implants, including Zeus spinal fixation system, Katia anterior cervical fixation system, and Adena spinal fixation system [2] - Core technologies include multi-plane adjustment, flexible extension arm percutaneous screw technology, and new generation intervertebral disc prostheses [2] Group 2: Strategic Collaborations - The company has formed a strategic partnership with SPINEART SA to collaborate in non-fusion technology and adjacent segment degeneration [1] - Focus on innovation in cervical spine products to provide better treatment options for doctors and patients in China [1] Group 3: Market Expansion and Certifications - Zeus spinal system has received certification in the United States, representing the latest generation of spinal high-end fixation systems [2] - The product addresses a wide range of indications, including vertebral fractures, degeneration, and deformities, with a comprehensive design for both open and minimally invasive surgeries [2]

证券代码：688085 证券简称：三友医疗 公告编号：2023-035 上海三友医疗器械股份有限公司（以下简称"公司"）于 2023 年 10 月 28 日发 布公司《2023 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财务状况、发展理念，公司计划于 2023 年 11 月 22 日下午 14:00-15:00 举行第三季度业绩说明会，此次活动将采用网络文字互动的方式举行， 投资者可登录上海证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线 上互动交流。 一、 说明会类型 上海三友医疗器械股份有限公司 关于召开2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 11 月 22 日(星期三) 下午 14:00-15:00 会议召开方式：上证路演中心网络文字互动 会议召开地点：上海证券交易所上证路演中心（http://roadshow.sseinfo.co m/） 投资 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥76,703,267.41, a decrease of 58.51% compared to the same period last year[7]. - The net profit attributable to shareholders for Q3 2023 was ¥3,370,903.57, down 92.97% year-on-year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥580,819.91, a decline of 98.43% compared to the previous year[7]. - The basic earnings per share for Q3 2023 was ¥0.01, a decrease of 94.74% year-on-year[7]. - The net profit for the first three quarters of 2023 was CNY 75,220,211.77, down from CNY 128,402,109.87 in the same period of 2022, indicating a decline of approximately 41.5%[29]. - The company's operating revenue for the first three quarters of 2023 was CNY 481,533,122.53, compared to CNY 358,927,163.10 in the same period of 2022, marking an increase of about 34.1%[28]. - The net profit attributable to the parent company for Q3 2023 was CNY 66,288,466.76, a decrease from CNY 124,614,640.34 in Q3 2022, representing a decline of approximately 46.8%[30]. - The basic and diluted earnings per share for Q3 2023 were both CNY 0.27, down from CNY 0.50 in the same period last year, indicating a decrease of 46%[31]. Research and Development - The total R&D investment for Q3 2023 was ¥17,266,765.60, a decrease of 4.30% compared to the same period last year[7]. - The company reported a total R&D investment of RMB 47.0987 million for the year, an increase of 8.83% compared to the same period last year, with R&D expenses accounting for 13.12% of total revenue, up 4.13 percentage points year-on-year[18]. - Research and development expenses for the third quarter of 2023 were CNY 47,098,667.84, an increase from CNY 43,277,295.42 in the previous year, reflecting a growth of approximately 8.5%[29]. - The company is committed to increasing R&D investment to drive innovation and improve treatment outcomes in response to market challenges[18]. Assets and Liabilities - The total assets as of September 30, 2023, were ¥2,163,329,553.12, a decrease of 1.28% from the end of the previous year[8]. - The company's total liabilities decreased to CNY 184,540,522.49 from CNY 278,349,770.67, representing a reduction of about 33.7%[26]. - The total liabilities decreased to ¥210,908,470.23 in Q3 2023 from ¥232,256,680.92 in Q3 2022, a reduction of approximately 9.2%[36]. - The total equity attributable to shareholders increased to CNY 1,886,905,143.47 from CNY 1,839,743,607.05, showing a rise of approximately 2.6%[26]. - The company's total assets amounted to CNY 2,163,329,553.12, a decrease from CNY 2,191,365,967.39 at the end of 2022, reflecting a decline of approximately 1.3%[23]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥167,359,458.96, an increase of 74.47% compared to the same period last year[7]. - Cash flow from operating activities for the first three quarters of 2023 was CNY 167,359,458.96, an increase from CNY 95,923,327.44 in the same period of 2022, reflecting a growth of approximately 74.5%[31]. - Cash inflow from investment activities totaled CNY 277,134,002.33, a sharp decline of 77.2% compared to CNY 1,214,083,753.29 in the previous year[40]. - Cash and cash equivalents at the end of the period reached CNY 463,851,326.68, an increase of 99.4% from CNY 232,530,124.00 in the previous year[42]. Market Impact - The company attributed the significant decline in revenue to the impact of national policies on high-value consumables in the spinal medical field, leading to a decrease in surgical volumes and sales[13]. - The implementation of national centralized procurement for high-value spinal consumables has led to a significant decline in terminal surgical volumes, adversely affecting the company's sales performance[18]. - The company’s total revenue and performance have been impacted by the decline in surgical volumes due to national policies affecting the medical field[18]. - The company is focusing on innovation in therapy and collaboration with medical engineering to mitigate the short-term negative impacts of national procurement policies[18]. Product Development and Certifications - The company received approval for its 3D printed "metal additive manufacturing interbody fusion device" from the National Medical Products Administration, enhancing its product offerings in the spinal surgery market[19]. - The Zeus spinal system received FDA 510(k) certification, expanding the company's product line and enhancing its competitive edge in the international market[20]. - The company obtained EU MDR CE certification for all its spinal fixation systems, allowing for continued legal sales in relevant overseas markets and supporting international business development[21]. - The company's core competitive capabilities and overall strength are expected to improve with the introduction of new products and certifications[20].

证券代码：688085 证券简称：三友医疗 公告编号：2023-034 上海三友医疗器械股份有限公司 关于公司获得欧盟医疗器械法规（MDR）认证 的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海三友医疗器械股份有限公司（以下简称"公司"）近日获得由欧盟 CE 认 证公告机构 UDEM ADRIATIC d.o.o.按照欧盟医疗器械法规 Medical Devices Regulation (EU) 2017/745（简称"MDR"）认证规则签发的欧盟认证证书，现 将具体情况公告如下： 一、证书内容 证书名称：EU Quality Management System Certificate（欧盟 MDR 认证证 书） 二、对公司的影响 1 欧盟医疗器械法规取代了欧盟原有的《医疗器械指令 93/42/EEC》（Medical Devices Directive，MDD）和《有源植入类医疗器械指令 90/385/EEC》（Active Implantable Medical Device Directive， ...

证券代码：688085 证券简称：三友医疗 公告编号：2023-033 上海三友医疗器械股份有限公司 关于持股 5%以上股东权益变动超过 1%的提示性公告 上海隹正企业管理合伙企业（有限合伙）（以下简称"上海隹正"）保证向 上海三友医疗器械股份有限公司（以下简称"公司"或"三友医疗"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确 性和完整性依法承担法律责任。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司于 2023 年 10 月 19 日，收到公司股东上海隹正发来的《关于股份权益 变动超过 1%的告知函》，自 2023 年 9 月 14 日至 2023 年 10 月 18 日期间，上 海隹正通过大宗交易方式减持公司股份 4,969,000 股，占目前公司总股本的 2.00%，现将其有关权益变动情况告知如下： 一、 本次权益变动情况 本次权益变动为持股 5%以上非第一大股东减持； 本次权益变动属于股份减持，不触及要约收购。不会使公司实际控制 人发生变化。本次权益变动通 ...

上海三友医疗器械股份有限公司（以下简称"公司"）近日 U.S. Food and Drug Administration（美国食品药品监督管理局，以下简称"FDA"）的通知， 公司 Zeus 脊柱系统产品获得美国 FDA 510K 认证，现将具体情况公告如下： 上海三友医疗器械股份有限公司 关于 Zeus 脊柱系统产品获得 美国 FDA510（K）认证的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688085 证券简称：三友医疗 公告编号：2023-032 一、产品注册情况 1、获批主体：上海三友医疗器械股份有限公司（英文名称：Shanghai Sanyou Medical Co, LTD） 2、产品名称：Zeus Spinal System 3、应用领域：Zeus脊柱系统用于骨骼成熟的患者非颈椎后路固定辅助融合， 有以下适应症：退行性椎间盘疾病（定义为背痛椎间盘源性，病史和放射学研究 证实椎间盘变性）；脊椎滑脱；创伤（即骨折或脱位）；椎管狭窄；弯曲（即，后 凸和/或前凸）；肿瘤；假关节；和/或 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, reaching RMB 500 million, representing a 25% year-over-year growth[1]. - The company's operating revenue for the first half of 2023 was ¥282,223,895.69, a decrease of 4.86% compared to ¥296,652,455.66 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2023 was ¥62,917,563.19, down 17.92% from ¥76,656,198.74 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥48,262,674.44, a decline of 32.75% compared to ¥71,770,400.02 in the same period last year[21]. - The net cash flow from operating activities increased by 50.69% to ¥113,516,155.17 from ¥75,333,121.16 in the previous year[21]. - The company's total assets at the end of the reporting period were ¥2,220,450,938.16, reflecting a 1.33% increase from ¥2,191,365,967.39 at the end of the previous year[21]. - The basic earnings per share for the first half of 2023 decreased by 19.35% to CNY 0.25 compared to CNY 0.31 in the same period last year[22]. - The weighted average return on equity fell by 1.09 percentage points to 3.37% from 4.46% year-on-year[22]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 30%[3]. - The company is expanding its market presence, targeting a 10% increase in market share in the Asia-Pacific region by the end of 2023[5]. - The management has outlined a new strategy to enhance online sales channels, aiming for a 50% increase in e-commerce revenue by the end of 2023[8]. - The company is expanding its international market presence, particularly in Europe, the United States, and Australia, while maintaining its leading position in the domestic orthopedic market[32]. - The company is committed to expanding its market share in the minimally invasive spinal sector through innovative product development[49]. Research and Development - Research and development investments have increased by 30%, focusing on innovative medical technologies and improving existing product lines[6]. - The company has established a comprehensive product R&D system and framework, focusing on original innovation and clinical research collaboration with medical institutions[30]. - The company has a robust R&D team with advanced equipment, ensuring the effectiveness and reliability of its products[34]. - The total R&D investment for the reporting period was ¥29,831,902.24, representing an 18.21% increase compared to ¥25,235,354.42 in the same period last year[46]. - R&D investment accounted for 10.57% of operating revenue, an increase of 2.06 percentage points from 8.51% in the previous year[46]. Product Development and Innovation - New product launches are expected to contribute an additional RMB 100 million in revenue, with two new orthopedic devices set to be released by Q4 2023[4]. - The company has launched several innovative products, including the Adena thoracolumbar spinal internal fixation series and the Zina spinal minimally invasive fixation series, enhancing its competitive edge in the market[57]. - The company is actively developing new technologies, including next-generation surgical robots that integrate various imaging and sensor data for improved surgical precision[31]. - The company has developed a new modular internal fixation product for lumbar spine surgery, compatible with 4.5, 5.5, and 6.0 rods, improving treatment options for various spinal conditions[41]. - The company is focusing on developing minimally invasive techniques that require smaller incisions, thus reducing surgical trauma and improving patient safety[38]. Acquisitions and Partnerships - The company has completed a strategic acquisition of a smaller competitor, which is expected to enhance its product offerings and increase operational efficiency[7]. - A strategic partnership was established with SPINEART SA to collaborate on non-fusion technology, specifically the BAGUERA-C artificial cervical disc replacement technology[71]. - The company has established partnerships with multiple top-tier hospitals to better understand clinical needs and improve product design, leading to significant advancements in spinal surgery techniques[57]. Risk Management - The company has identified potential risks in supply chain disruptions, which could impact production timelines and costs[9]. - The company is facing risks related to core technology leakage and talent loss, which could adversely affect its innovation capabilities[78][79]. - The company is committed to enhancing its marketing network and product sales to mitigate risks associated with large inventory balances[81]. Environmental Responsibility - The company generated approximately 410 tons of CO2 equivalent emissions reduction through clean energy initiatives during the reporting period[122]. - A distributed photovoltaic power station was constructed on the rooftop of the wholly-owned subsidiary, which has generated about 410,000 kWh of electricity since it was connected to the grid on April 12, 2023[122]. - The company has implemented measures to reduce waste generation and environmental pollution through process improvements and material recycling[122]. - The company does not belong to the list of key pollutant discharge units published by environmental protection authorities[118]. Corporate Governance - The company has not proposed any profit distribution or capital reserve transfer plans for the first half of 2023[114]. - There were changes in the board, with Gu Shaoyu being elected as an independent director following the resignation of Song Rui[112]. - The company has committed to long-term stockholding by major shareholders, including actual controllers, with no sales during the lock-up period[140]. - The company will implement stock repurchase measures if the stock price closes below the latest audited net asset value per share for 20 consecutive trading days[142].